# Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis

> **NCT00665639** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 454 (actual)

## Conditions studied

- Candidiasis, Oral

## Interventions

- **DRUG:** micafungin
- **DRUG:** caspofungin

## Key facts

- **NCT ID:** NCT00665639
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2004-12
- **Final completion:** 2004-12
- **Target enrollment:** 454 (ACTUAL)
- **Last updated:** 2014-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00665639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00665639, "Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT00665639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*